Women, dyslipoproteinemia, and estrogens

Endocrinology and Metabolism Clinics of North America

Volumn 27, Issue 3, 1998, Pages 627-639

  LaRosa, J C ^a  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ESTROGEN;

CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DYSLIPOPROTEINEMIA; ESTROGEN THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; REVIEW;

EID: 0031719982     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70030-X     Document Type: Article

References (69)

1. M.R. Adams J.K. Williams J.R. Kaplan Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness Arterioscler Thromb Vasc Biol 15 1995 562
2. H. Aldercrutz H. Markkanen S. Watanabe Plasma concentrations of phytoestrogens in Japanese men Lancet 342 1993 1209
3. M.S. Anthony T.B. Clarkson B.C. Bullock Soy protein versus soy phytoestrogens (isoflavones) in the prevention of coronary artery atherosclerosis of cynomolgus monkeys Circulation 94 suppl 1 1996 I 265
4. J.A. Arrowood M.E. Willis M.R. Ficher Endothelial function is preserved in postmenopausal women on hormone replacement therapy at risk for coronary disease Circulation 94 suppl 1 1996 279
5. R.J. Barnard Effects of life-style modification on serum lipids Arch Intern Med 151 1991 1389
6. E. Barrett-Connor J.L. Witztum M. Holdbrook A community study of high density lipoproteins in adult noninsulin-dependent diabetes Am J Epidemiol 117 1983 186
7. R.P. Byington J.W. Jukema J.T. Salonen Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program Circulation 92 1995 2419
8. P.M. Clifton M. Abbey M. Noakes Body fat distribution is a determinant of the high-density lipoprotein response to dietary fat and cholesterol in women Arterioscler Thromb Vasc Biol 15 1995 1070
9. R.S. Cooper J.L. Ghali Coronary heart disease: Black-white differences Cardiovasc Clin 21 1991 205
10. A.M. Dnistrian M.K. Schwartz E.J. Greenberg Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy Clin Chim Acta 223 1993 43 52
11. J.R. Downs M. Clearfield S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS JAMA 279 1998 1615
12. A. Dziewulska-Bokiniec J. Wojtacki J. Skokowski Lipoprotein profile in breast cancer women: Effect of tamoxifen treatment Neoplasma 41 1994 337
13. N. Ernst P. Bowen M. Fisher Changes in plasma lipids and lipoproteins after a modified fat diet Lancet 1 1980 111
14. M. Falkeborn I. Persson Adami H.-O. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement Br J Obstet Gynaecol 99 1992 821
15. E. Farish H.A. Rolton J.F. Barnes Lipoprotein(a) concentrations in postmenopausal women taking norethisterone BMJ 303 1991 694
16. A.R. Folsom S.A. Kaye T.A. Sellers Body fat distribution and 5-year risk of death in older women JAMA 269 1993 483
17. P. Gardner B.L. Hudson Advance report of final mortality statistics, 1993 Monthly Vital Statisics Report USDHHS 44 1996 12 13
18. M.G. Goldschmid E. Barrett-Connor S.L. Edelstein Dyslipidemia and ischemic heart disease mortality among men and women with diabetes Circulation 89 1994 991
19. W.J. Gradishar V.C. Jordan Clinical potential of new antiestrogens J Clin Oncol 15 1997 840
20. D. Grady S.M. Rubin D.B. Petitti Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med 117 1992 1016
21. B. Griffin E. Farish D. Walsh Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause Clin Endocrinol 39 1993 463
22. F. Grodstein M.J. Stampfer G.A. Colditz Postmenopausal hormone therapy and mortality N Engl J Med 336 1997 1769
23. Group of Physicians of the Newcastle upon Tyne Region Trial of clofibrate in the treatment of ischaemic heart disease BMJ 4 1971 767
24. G.H. Hartung C.E. Moore R. Mitchell Relationship of menopausal status and exercise level to HDL cholesterol in women Exp Aging Res 10 1984 13
25. H. Hauner H.H. Ditschuneit S.B. Pal Fat distribution, endocrine and metabolic profile in obese women with and without hirsutism Metabolism 37 1988 281
26. D.M. Herrington Estrogen and heart disease: Trials to prevent tribulations Mauritas 27 1977 199
27. J.P. Kane M.J. Malloy T.A. Ports Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 264 1990 3007
28. A.S. Krolewski J.F. Warram P. Valsania Evolving natural history of coronary artery disease in diabetes mellitus Am J Med 90 suppl 2A 1991 2A 56S
29. R.S. Kushwaha Female sex steroid hormones and lipoprotein metabolism Curr Opin Lipidology 3 1992 167
30. J.C. LaRosa Triglycerides and coronary risk in women and the elderly Arch Intern Med 157 1997 961
31. J.C. LaRosa L.E. Chambless M.H. Criqui Patterns of dyslipoproteinemia in selected North American populations: The Lipid Research Clinics Program Prevalance Study Circulation 73 suppl I 1982 I 12
32. Lipid Research Clinics Population Studies Data Book, The Prevalence Study, vol 1. US Department of Health and Human Services, NIH Publication No. 80–1527. Washington, DC, US Government Printing Office, 1980.
33. R.A. Lobo Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women J Clin Endocrinol Metab 73 1991 925
34. R.R. Love D.A. Wiebe J.M. Feyzi Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment J Natl Cancer Inst 86 1994 1534
35. T.A. Manolio T.A. Pearson N.K. Wenger Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop Ann Epidemiol 2 1992 161
36. 3-C, apoprotein-B, and Lp(a) Am J Clin Nutr 40 1984 468
37. C.C. McDonald F.E. Alexander B.W. Whyte Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish Cancer Trials Breast Group BMJ 311 1995 977
38. McGill H.C. Jr C.A. McMahan G.T. Malcom Effects of serum lipoproteins and smoking on atherosclerosis in young men and women: The PDAY Research Group, Pathobiological Determinants of Atherosclerosis in Youth Arterioscler Thromb Vasc Biol 17 1997 95
39. R.P. Mensink M.B. Katan Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women Lancet 8525 1987 122
40. M. Miettinen O. Turpeinen M.J. Karvonen Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: A twelve-year clinical trial in men and women Lancet 2 1972 835
41. R.F. Nease J.M. Ross The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffs Am J Med 99 1995 180
42. New York Times. Cholesterol drugs shown to cut healthy group's risk. Nov 13, 1997, p A13.
43. M. Notelovitz E.B. Feldman M. Gillespy Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: A controlled, comparative 12-month clinical trial Am J Obstet Gynecol 160 1989 1269
44. B.M. Psaty S.R. Heckbert D. Atkins The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women Arch Intern Med 154 1994 1333
45. Research Committee of the Scottish Society of Physicians Ischaemic heart disease: A secondary prevention trial using clofibrate BMJ 4 1971 775
46. V.A. Rifici A.K. Khachadurian The inhibition of low-density lipoprotein oxidation by 17-β estradiol Metabolism 41 1992 1110
47. L. Rosenberg D.W. Kaufman S.P. Helmrich Myocardial infarction and cigarette smoking in women younger than 50 years of age JAMA 253 1985 2965
48. Sacks F.M. Pfeffer M.A. Moye L.A. for the Cholesterol and Recurrent Events Trial Investigators (CARE): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001
49. M. Sandkamp G. Assmann Lipoprotein(a) in PROCAM participants and young myocardial infarction survivors Scanu A.M. Lipoprotein(a) 1990 Academic Press New York
50. D.A. Shewmon J.L. Stock K.M. Heiniluoma Tamoxifen lowers Lp(a) in males with heart disease Circulation 86 suppl I 1992 I 338
51. J.T. Soler A.R. Folsom L.H. Kushi Association of body fat distribution with plasma lipids, lipoproteins, apolipoproteins AI and B in postmenopausal women Atherosclerosis 79 1989 21 27
52. K.E. Sorenson I. Dourp A.P. Hermann Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function Circulation 97 1998 1234
53. M.R. Soma I. Osnago-Gadda R. Paoletti The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women Arch Intern Med 153 1993 1462
54. L. Speroff A. DeCherney Burkman R.T. Jr the Advisory Board for the New Progestins Evaluation of a new generation of oral contraceptives Obstet Gynecol 81 1993 1034
55. M.J. Stampfer W.C. Willett G.A. Colditz A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases N Engl J Med 319 1988 1313
56. M.J. Stampfer G.A. Colditz W.C. Willett Menopause and heart disease: A review Ann NY Acad Sci 592 1990 193
57. Sullivan J.M. Vander Zwaag R. J.P. Hughes Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women Arch Intern Med 150 1990 2557
58. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel II) JAMA 269 1993 3015
59. M. Thangaraju K. Kumar R. Gandhirajan Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer Cancer 73 1994 659
60. The Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383
61. Wagner J.D. St Clair R.W. Schwenke D.C. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys Arterioscler Thromb 12 1992 717
62. J.D. Wagner S.A. Washburn L. Zhang A non-feminizing conjugated equine estrogen decreases arterial LDL degradation and improves vascular reactivity in male rhesus monkeys Circulation 92 suppl 1 1995 I 627
63. J.M.E. Walsh D. Grady Treatment of hyperlipidemia in women JAMA 274 1995 1152
64. D. Waters L. Higginson Gladstone P. the CCAIT Study Group Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 1994 959
65. J.K. Williams M.R. Adams H.S. Klopfenstein Estrogen modulates responses of atherosclerotic coronary arteries Circulation 81 1990 1680
66. J.K. Williams J.D. Wagner Z. Li Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys Arterioscler Thromb Vasc Biol 17 1997 403
67. P.A. Wolf Risk factors for stroke: How they differ from those for coronary artery disease Perspectives in Lipid Disorders 1986 Postgraduate Medicine: Custom Communications Morris Plains, NJ
68. Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 273 1995 199
69. O. Ylikorkala T. Kuusi M.J. Tikkanen Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins J Clin Endocrinol Metab 65 1987 1238